MedTrace Logo

Alectinib-induced Endocrine Toxicity

NCT06339554 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 98

Last updated 2024-04-01

No results posted yet for this study

Summary

The experimental Cohort A (male ALK+ ANSCLC patients receiving alectinib), the control Cohort B (female ALK+ ANSCLC patients receiving alectinib) and control Cohort C (male NON-ALK ANSCLC patients) were prospectively evaluated for full hormone assessment of androgen deficiency, AT 8 weeks after treatment start and in case of reported suspected symptoms. Patients with major sexual dysfunctions were referred to endocrinologist.

Conditions

  • NSCLC Stage IV

Interventions

DRUG

Alectinib 150 MG [Alecensa]

First line treatment for cohorts A and B

Sponsors & Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-12
Primary Completion
2023-10-30
Completion
2023-10-30
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06339554 on ClinicalTrials.gov